Peng L, Zhang X, Zhang ML, Jiang T, Zhang PJ. Diagnostic value of matrix metalloproteinases 2, 7 and 9 in urine for early detection of colorectal cancer. World J Gastrointest Surg 2023; 15(5): 931-939 [PMID: 37342853 DOI: 10.4240/wjgs.v15.i5.931]
Corresponding Author of This Article
Peng-Jun Zhang, PhD, Doctor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China. zhangpj301@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. May 27, 2023; 15(5): 931-939 Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.931
Diagnostic value of matrix metalloproteinases 2, 7 and 9 in urine for early detection of colorectal cancer
Liu Peng, Xin Zhang, Man-Li Zhang, Tao Jiang, Peng-Jun Zhang
Liu Peng, Xin Zhang, Peng-Jun Zhang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Beijing 100142, China
Man-Li Zhang, Tao Jiang, Division of Medicine Innovation Research, Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Peng L, Jiang T and Zhang PJ designed the study; Peng L, Zhang X performed the research; Peng L, Jiang T, Zhang ML and Zhang PJ analyzed the date; Peng L wrote the paper; Jiang T and Zhang PJ revised the manuscript for final submission; Peng L and Zhang X contributed equally to this study; Jiang T and Zhang PJ are the co-corresponding authors.
Supported bythe National Key Research and Development Program of China, No. 2020YFC2004604 and 2020YFC2002700.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Peking University Cancer Hospital & Institute.
Informed consent statement: All study participants or their legal guardian provided written informed consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The study participants provided informed consent for data sharing. No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Peng-Jun Zhang, PhD, Doctor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China. zhangpj301@126.com
Received: March 13, 2023 Peer-review started: March 13, 2023 First decision: March 28, 2023 Revised: March 29, 2023 Accepted: April 7, 2023 Article in press: April 7, 2023 Published online: May 27, 2023 Processing time: 74 Days and 7.2 Hours
ARTICLE HIGHLIGHTS
Research background
Early diagnosis and early treatment are critical to improved colorectal cancer (CRC) diagnosis and treatment.
Research motivation
A noninvasive biomarker with high diagnostic performance is urgently needed for the early clinical diagnosis of CRC.
Research objectives
To evaluate the diagnostic value of matrix metalloproteinases (MMPs) 2, 7 and 9 for the early detection of CRC.
Research methods
Serum carcinoembryonic antigen (CEA) and urine MMP2, MMP7, and MMP9 levels were measured in 59 healthy controls, 47 patients with colon polyps and 82 patients with CRC. The independent and combined diagnostic values of the indicators for the detection of CRC were compared.
Research results
A model for CRC detection using CEA, MMP2, MMP7 and MMP9 exhibited an area under the curve (AUC) of 0.977. For early-stage and advanced-stage CRC, the model AUCs were 0.975 and 0.979, respectively. To distinguish the colorectal polyp patients from the CRC patients, the model using CEA, MMP7 and MMP9 levels produced an AUC of 0.849. For early-stage and advanced-stage CRC, the AUCs were 0.818 and 0.875, respectively.
Research conclusions
Compared with CEA alone, the diagnostic performance of a model combining CEA, MMP2, MMP7 and MMP9 established in this study was significantly improved.
Research perspectives
Validation of the model built in our study using a larger sample size should be performed.
